DUBLIN–(BUSINESS WIRE)–The “Growth Differentiation Factor 8 – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Summary
According to the recently published report ‘Growth Differentiation Factor 8 – Pipeline Review, H2 2019’; Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 10 molecules.
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.
The report ‘Growth Differentiation Factor 8 – Pipeline Review, H2 2019’ outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 3 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Musculoskeletal Disorders, Hematological Disorders and Oncology which include indications Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Anemia, Charcot-Marie-Tooth Disease, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Limb-Girdle Muscular Dystrophy, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis, Neuro Muscular Disorders, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) and Thalassemia.
Scope
- The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
- The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Topics Covered:
- Introduction
- Report Coverage
- Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Overview
- Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Companies Involved in Therapeutics Development
- Acceleron Pharma Inc
- Biogen Inc
- Bioleaders Corp
- Chugai Pharmaceutical Co Ltd
- PeptiDream Inc
- Pfizer Inc
- Regeneron Pharmaceuticals Inc
- Scholar Rock Inc
- Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Drug Profiles
- ALG-802 – Drug Profile
- BIIB-110 – Drug Profile
- BLSM-22 – Drug Profile
- domagrozumab – Drug Profile
- efmitermant alfa – Drug Profile
- luspatercept – Drug Profile
- RG-70240 – Drug Profile
- SRK-015 – Drug Profile
- Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy – Drug Profile
- trevogrumab – Drug Profile
- Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Dormant Products
- Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Discontinued Products
- Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Product Development Milestones
-
Featured News & Press Releases
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dyoq4p
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900